Barclays Reaffirms Equal Weight Rating for uniQure (QURE)

uniQure N.V. (NASDAQ:QURE) is one of the 7 best small-cap healthcare stocks to buy according to hedge funds.

On March 23, Barclays analyst Eliana Merle reduced the price target on uniQure N.V. (NASDAQ:QURE) from $31 to $25. The analyst reaffirmed an Equal Weight rating on the shares, which still offer a potential upside of more than 69% despite the downward revision.

Romaset/Shutterstock.com

Although the exit of Vinay Prasad from the FDA could have a positive impact, there are still risks associated with the company’s regulation. According to the analyst, a Phase 3 clinical trial for Huntington’s disease will be required for the company.

On March 11, Mizuho increased the firm’s price target on uniQure N.V. (NASDAQ:QURE) from $12 to $35. The firm upgraded the rating from Neutral to Outperform, which currently offers an upside potential of 137%.

Mizuho cited the recent departure of Dr. Vinay Prasad from the U.S. Food and Drug Administration, noting it could signal a more flexible regulatory environment. It added that this shift may reopen a path toward approval based on existing data or alternative trial designs, supporting a more constructive outlook on the shares.

uniQure N.V. (NASDAQ:QURE) is focused on developing therapeutics for patients suffering from rare and deadly diseases. Its product portfolio includes HEMGENIX, AMT-260, AMT-162, and AMT- 130. It targets various medical conditions such as hemophilia B, Huntington’s disease, mesial temporal lobe epilepsy, and more.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.